ONKURE THERAPEUTICS INC-A (OKUR) Stock Price, Quote, News and Overview
NASDAQ:OKUR - Nasdaq - US68277Q1058 - Common Stock - Currency: USD
OKUR Quote, Performance and Key Statistics
5.46
0 (0%)
The current stock price of OKUR is 5.46 USD. In the past month the price increased by 1.49%.
OKUR Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About OKUR
Company Profile
Onkure Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Boulder, Colorado and currently employs 8 full-time employees. The company went IPO on 2021-04-09. OnKure Therapeutics, Inc., formerly Reneo Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. Using a structure-based drug design platform, the Company is building a robust pipeline of tumor-agnostic candidates. The firm is developing OKI-219, a selective PI3KαH1047R inhibitor, as its lead program. OKI-219 is being evaluated in a Phase I clinical trial in solid tumor patients with PI3KαH1047R mutations, including breast cancer. The firm is also focused on targeting oncogenic PI3Kα and has multiple programs designed to enable targeting of this key oncogene.
Company Info
ONKURE THERAPEUTICS INC-A
6707 Winchester Circle, Suite 400
Boulder COLORADO US
Employees: 8
Company Website: https://onkuretherapeutics.com/
Investor Relations: https://investors.reneopharma.com/overview/default.aspx
Phone: 17203072892
ONKURE THERAPEUTICS INC-A / OKUR FAQ
What is the stock price of ONKURE THERAPEUTICS INC-A today?
The current stock price of OKUR is 5.46 USD.
What is the ticker symbol for ONKURE THERAPEUTICS INC-A stock?
The exchange symbol of ONKURE THERAPEUTICS INC-A is OKUR and it is listed on the Nasdaq exchange.
On which exchange is OKUR stock listed?
OKUR stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ONKURE THERAPEUTICS INC-A stock?
11 analysts have analysed OKUR and the average price target is 34.88 USD. This implies a price increase of 538.9% is expected in the next year compared to the current price of 5.46. Check the ONKURE THERAPEUTICS INC-A stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ONKURE THERAPEUTICS INC-A worth?
ONKURE THERAPEUTICS INC-A (OKUR) has a market capitalization of 72.84M USD. This makes OKUR a Micro Cap stock.
How many employees does ONKURE THERAPEUTICS INC-A have?
ONKURE THERAPEUTICS INC-A (OKUR) currently has 8 employees.
What are the support and resistance levels for ONKURE THERAPEUTICS INC-A (OKUR) stock?
ONKURE THERAPEUTICS INC-A (OKUR) has a resistance level at 6.16. Check the full technical report for a detailed analysis of OKUR support and resistance levels.
Should I buy ONKURE THERAPEUTICS INC-A (OKUR) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of OKUR, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of OKUR, evaluating the profitability, health, valuation and growth aspects
- ONKURE THERAPEUTICS INC-A (OKUR) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ONKURE THERAPEUTICS INC-A (OKUR) Sales and EPS estimates to see what analysts future expectations are.
- ONKURE THERAPEUTICS INC-A (OKUR) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ONKURE THERAPEUTICS INC-A (OKUR) Insider and Institutional Ownership to learn about the owners and their transactions.
- ONKURE THERAPEUTICS INC-A (OKUR) Stock Chart to make your own analysis
- ONKURE THERAPEUTICS INC-A (OKUR) Latest news and press-releases to stay up to date.
Does ONKURE THERAPEUTICS INC-A (OKUR) stock pay dividends?
OKUR does not pay a dividend.
When does ONKURE THERAPEUTICS INC-A (OKUR) report earnings?
ONKURE THERAPEUTICS INC-A (OKUR) will report earnings on 2025-03-26, after the market close.
What is the Price/Earnings (PE) ratio of ONKURE THERAPEUTICS INC-A (OKUR)?
ONKURE THERAPEUTICS INC-A (OKUR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.91).
What is the Short Interest ratio of ONKURE THERAPEUTICS INC-A (OKUR) stock?
The outstanding short interest for ONKURE THERAPEUTICS INC-A (OKUR) is 11.29% of its float. Check the ownership tab for more information on the OKUR short interest.
OKUR Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to OKUR.
OKUR Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to OKUR. No worries on liquidiy or solvency for OKUR as it has an excellent financial health rating, but there are worries on the profitability.
OKUR Financial Highlights
Over the last trailing twelve months OKUR reported a non-GAAP Earnings per Share(EPS) of -5.91. The EPS decreased by -148.32% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -52.85% | ||
| ROE | -55.44% | ||
| Debt/Equity | 0 |
OKUR Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 85% to OKUR. The Buy consensus is the average rating of analysts ratings from 11 analysts.